1 Recommendations

1.1 Ramucirumab alone or with paclitaxel is not recommended within its marketing authorisation for advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy.

1.2 People whose treatment with ramucirumab was started within the NHS before this guidance was published should be able to continue treatment until they and their clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)